Ims Capital Management buys $1,247,642 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Ims Capital Management scooped up 4,772 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 15,578 shares of Gilead Sciences which is valued at $1,247,642.Gilead Sciences makes up approximately 1.41% of Ims Capital Management’s portfolio.

Other Hedge Funds, Including , Bourgeon Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 4,400 additional shares and now holds a total of 6,900 shares of Gilead Sciences which is valued at $552,621. Gilead Sciences makes up approx 0.34% of Bourgeon Capital Management’s portfolio.First Citizens Bank Trust Co reduced its stake in GILD by selling 24,917 shares or 17.61% in the most recent quarter. The Hedge Fund company now holds 116,611 shares of GILD which is valued at $9,267,076. Gilead Sciences makes up approx 0.80% of First Citizens Bank Trust Co’s portfolio.Huntington National Bank reduced its stake in GILD by selling 86,574 shares or 24.81% in the most recent quarter. The Hedge Fund company now holds 262,412 shares of GILD which is valued at $21,462,677. Gilead Sciences makes up approx 0.52% of Huntington National Bank’s portfolio.Macguire Cheswick Tuttle Investment Counsel reduced its stake in GILD by selling 3,380 shares or 2.31% in the most recent quarter. The Hedge Fund company now holds 142,645 shares of GILD which is valued at $12,345,925. Gilead Sciences makes up approx 2.65% of Macguire Cheswick Tuttle Investment Counsel’s portfolio.

Gilead Sciences closed down -0.67 points or -0.83% at $79.74 with 95,11,596 shares getting traded on Monday. Post opening the session at $80.46, the shares hit an intraday low of $79.01 and an intraday high of $80.79 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *